scispace - formally typeset
C

Chang-Shen Lin

Researcher at Kaohsiung Medical University

Publications -  68
Citations -  6760

Chang-Shen Lin is an academic researcher from Kaohsiung Medical University. The author has contributed to research in topics: Cancer & Carcinogenesis. The author has an hindex of 22, co-authored 60 publications receiving 6079 citations. Previous affiliations of Chang-Shen Lin include Tri-Service General Hospital & National Sun Yat-sen University.

Papers
More filters
Journal ArticleDOI

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

TL;DR: The mechanisms of DDR and their crucial roles in cancer therapy based on the concepts of synthetic lethality and ICB are discussed and the contemporary clinical trials of DDR-targeting and ICb therapies in breast, colorectal, and pancreatic cancers are included.
Journal ArticleDOI

Cancer cell reprogramming to identify the genes competent for generating liver cancer stem cells.

TL;DR: The present review summarizes the current understanding of transcription factors involved in the generation of liver CSCs from liver cancer cell-derived iPSCs and how these contribute to oncogenesis, and discusses the modeling of liver cancer development.
Journal ArticleDOI

Generation of Human Stomach Cancer iPSC-Derived Organoids Induced by Helicobacter pylori Infection and Their Application to Gastric Cancer Research

TL;DR: The conditions required for stomach-cancer-derived organoids induced by Helicobacter pylori in vitro and the ability of such models for testing the use of anticancer agents are examined.
Book ChapterDOI

Application of Host Cell Reactivation in Evaluating the Effects of Anticancer Drugs and Environmental Toxicants on Cellular DNA Repair Activity in Head and Neck Cancer

TL;DR: The application of an easy, fast and measurable in vivo functional assay for nucleotide excision repair (NER) and DNA repair via homologous recombination and non-homologous end-joining (NHEJ) pathways is shown to examine the cellular DNA repair activity responding to anticancer drugs or environmental toxicants.
Journal ArticleDOI

Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.

TL;DR: The co-expression of FOXM1 and Aurora-A could be a reliable biomarker to predict the sorafenib response and prognosis of HCC patients.